CATANIA, Italy, Nov. 19, 2020 /PRNewswire/ -- SIFI, a leading ophthalmic company, announced today that it has achieved the full enrollment of 135 patients with Acanthamoeba keratitis (AK) in its ...
CATANIA, Italy, Sept. 30, 2024 /PRNewswire/ -- SIFI, a leading international ophthalmic company, announced that is has received a Notice of Allowance from the European Patent Office ("EPO") for ...
The treatment being studied, low concentration polihexanide (PHMB 0.02%), was first compounded and used in the 1990s to treat AK, introduced by a team co-led by this latest study's lead author, ...
CATANIA, Italy, Feb. 1, 2021 /CNW/ -- SIFI, a leading ophthalmic company, announced today the publication of clinical results from its Phase I trial of polihexanide in healthy volunteers. The paper ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved polihexanide (Akantior) to treat acanthamoeba keratitis. Acanthamoeba keratitis is an infection of the cornea, the clear ...
CATANIA, Italy, Nov. 19, 2020 /CNW/ -- SIFI, a leading ophthalmic company, announced today that it has achieved the full enrollment of 135 patients with Acanthamoeba keratitis (AK) in its pivotal ...
Polihexanide 0.08% Exhibits Compelling Safety and Tolerability Characteristics in Healthy Volunteers CATANIA, Italy, Feb. 1, 2021 /PRNewswire/ -- SIFI, a leading ophthalmic company, announced today ...
The treatment being studied, low concentration polihexanide (PHMB 0.02%), was first compounded and used in the 1990s to treat AK, introduced by a team co-led by this latest study’s lead author, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results